Quick Answer
Akebia Therapeutics, Inc. reported Cash and Equivalents of $184.84 million for fiscal year 2025.
Akebia Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $184.84M | +256.4% |
| 2024 | $51.87M | +20.8% |
| 2023 | $42.92M | -52.6% |
| 2022 | $90.47M | -39.6% |
| 2021 | $149.80M | -34.5% |
| 2020 | $228.70M | +55.1% |
| 2019 | $147.45M | +40.9% |
| 2018 | $104.64M | +49.2% |
| 2017 | $70.16M | -62.6% |
| 2016 | $187.34M | +276.3% |
| 2015 | $49.78M | +51.9% |
| 2014 | $32.78M | +54.5% |
| 2013 | $21.21M | +1192.8% |
| 2012 | $1.64M | -67.3% |
| 2011 | $5.01M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $166.44M | +389.3% | +21.2% |
| June 30, 2025 | $137.31M | +247.6% | +21.1% |
| March 31, 2025 | $113.37M | +170.2% | +118.6% |
| December 31, 2024 | $51.87M | +20.8% | +52.5% |
| September 30, 2024 | $34.02M | -26.9% | -13.9% |
| June 30, 2024 | $39.50M | -26.3% | -5.9% |
| March 31, 2024 | $41.96M | -26.3% | -2.2% |
| December 31, 2023 | $42.92M | -52.6% | -7.7% |
- Akebia Therapeutics, Inc. showed an increase of +256.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2011–2025 period, Akebia Therapeutics, Inc.’s cash and equivalents has grown by 3588.8% (from $5.01 million to $184.84 million).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: